AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03607435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectroscopy for Analyte Quantification
Description: Diabetic hospital staff participants subjected to the KBS-1 device (Test Article #01) will have a finger on their left hand pricked with a lancet and their blood glucose level read by a POC glucose monitor (Control Article #02). Next, they will have their interstitial fluid glucose level spectroscopically scanned from the palm of their left hand using the KBS-1 device, and blood (approximately 40µl), collected from their finger prick site, will be spectroscopically scanned using the RBA-1 device (Test Article #02). Hospital patients subjected to the RBA-1 device, who must already be prescribed a hospital lab blood test by their physician, will have approximately 40µl of their blood, collected from the venipuncture site, spectroscopically scanned using the RBA-1 device (Test Article #02).
Study NCT01908257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranitidine 150 mg
Study NCT02636946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham Bimatoprost SR
Description: Up to three Sham Bimatoprost SR administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Sham Bimatoprost SR administrations at Day 4 and Week 16 (Stage 2).
Study NCT02892591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Cannabis
Description: vaporized placebo plant material
Study NCT02892591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Cannabis
Description: vaporized placebo plant material
Study NCT02892591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Oxycodone
Description: oral placebo capsule
Study NCT02892591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Oxycodone
Description: oral placebo capsule
Study NCT01849536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish®
Study NCT02636946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham Bimatoprost SR
Description: Up to three Sham Bimatoprost SR administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Sham Bimatoprost SR administrations at Day 4 and Week 16 (Stage 2).
Study NCT02636946 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective Laser Trabeculoplasty
Description: Selective Laser Trabeculoplasty administered on Day 1.
Study NCT02636946 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Laser Trabeculoplasty
Description: Selective Laser Trabeculoplasty administered on Day 1.
Study NCT02636946 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Selective Laser Trabeculoplasty
Description: Sham Selective Laser Trabeculoplasty administered on Day 1.
Study NCT02636946 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Selective Laser Trabeculoplasty
Description: Sham Selective Laser Trabeculoplasty administered on Day 1.
Study NCT00780273 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankylos Implants
Description: ANKYLOS Implant System vs Certain PREVAIL Implant
Study NCT00780273 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biomet 3i Prevail Implants
Study NCT02781038 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Subjects in this group will not receive the pamphlet
Study NCT00306995 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB218352_15
Description: Non-adjuvanted pandemic influenza A formulation 1 vaccine
Study NCT00306995 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB218352_8
Description: Non-adjuvanted pandemic influenza A formulation 2 vaccine
Study NCT00306995 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB218352_4
Description: Non-adjuvanted pandemic influenza A formulation 3 vaccine
Study NCT00306995 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB218352_2
Description: Non-adjuvanted pandemic influenza A formulation 4 vaccine
Study NCT00306995 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB218352_8AL
Description: Pandemic influenza A formulation 2 aluminium-adjuvanted vaccine
Study NCT00306995 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB218352_4AL
Description: Pandemic influenza A formulation 3 aluminium-adjuvanted vaccine
Study NCT00306995 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB218352_2AL
Description: Pandemic influenza A formulation 4 aluminium-adjuvanted vaccine
Study NCT03004339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOR007 Ointment 2.0%
Study NCT03004339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOR007 Ointment 1.0%
Study NCT03004339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOR007 Ointment 0.3%
Study NCT00743041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques (EFT)
Description: EFT is an exposure therapy with a cognitive component, consisting of recall of a trauma along with a statement of self-acceptance, in combination with touching or tapping on a series of stress reduction points on the body
Study NCT00490139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Small molecule inhibitor
Study NCT01882439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: tablets, 5 mg BID x 6 months
Study NCT00490139 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Antibody
Study NCT00490139 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Antibody
Study NCT04608162 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Electromagnetic Field (PEMF)
Description: PEMF was administered to the whole body using a 1.8×0.6m mat
Study NCT01882439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: tablets, 10 mg BID x 6 months
Study NCT01882439 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets, to match tofacitinib 5 mg BID x 3 months
Study NCT01882439 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tofacitinib
Description: tablets, 5 mg BID x 3 months
Study NCT01882439 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets, to match tofacitinib 10 mg BID x 3 months
Study NCT04608162 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Description: Exercise program to facilitate bone health
Study NCT04608162 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise Program
Description: Exercise program to facilitate bone health
Study NCT04608162 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PEMF
Description: Patients received placebo PEMF
Study NCT02437604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Fp MDPI
Description: Fp MDPI 200 mcg, 1 inhalation
Study NCT02437604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: FS MDPI
Description: FS MDPI 200/12.5 mcg, 1 inhalation
Study NCT02437604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment C Flovent
Description: FLOVENT DISKUS 250 mcg, 2 inhalations
Study NCT02437604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment D: Advair
Description: ADVAIR DISKUS 500/50 mcg, 1 inhalation
Study NCT03381313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditioned word repetition training
Description: In the classical conditioning training the onset of the visual stimulus preceded that of the auditory stimulus with a short onset asynchrony, and both stimuli co-terminated. By contrast, in the training without conditioning the auditory stimulus was administered first and the visual stimulus appeared short after the off-set of the auditory one.
Study NCT03689244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag
Description: oral tablets containing 200 µg of selexipag. Depending on the iMTD, participants will receive 1 to 8 tablets at each administration
Study NCT03689244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets without active compound
Study NCT04464824 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT03303118 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hypoxia
Description: No drug or product will be used in this study. No medication will be give to the participants. No arm will be used for product administration.
Study NCT03400631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 0
Description: Dextrose injection at time 0
Study NCT03400631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspiration 0
Description: Aspiration only at time 0
Study NCT03400631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 1
Description: Dextrose injection at week 1
Study NCT03400631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspiration 1
Description: Aspiration only at week 1
Study NCT02332733 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TV003
Description: 10\^3 plaque forming units (PFU) of rDEN1 delta 30, 10\^3 PFU of rDEN2/4 delta 30(ME), 10\^3 PFU of rDEN3 delta 30/31-7164, and 10\^3 PFU of rDEN4 delta 30 to be administered as 0.5 mL by subcutaneous injection in the deltoid region of the upper arm or the thigh in pediatric participants
Study NCT02332733 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for TV003
Description: To be administered as 0.5 mL by subcutaneous injection in the deltoid region of the upper arm or the thigh in pediatric participants
Study NCT01638104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANX-042
Description: Reconstituted in Sterile Water for Injection, United States Pharmacopeia (USP) and administered by 12 hour continuous intravenous infusion with 5% dextrose in water (D5W), United States Pharmacopeia (USP)
Study NCT01638104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered once by 12 hour continuous intravenous infusion with D5W (USP)
Study NCT03263780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fluciclovine
Description: Imaging (comparing standard and experimental high resolution diffusion-weighted imaging \[DWI\] MRI with 18F-Fluciclovine)
Study NCT03132025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib and Capecitabine
Description: Combine Apatinib and Capecitabine to Maintain Treating Metastatic Colorectal Cancer
Study NCT03132025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Single Drug Capecitabine to Maintain Treating Metastatic Colorectal Cancer
Study NCT02285530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy
Description: TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m\^2), cisplatin(75 mg/m\^2), 5-Fu(750 mg/m\^2/day) for 5 days; 16 days later, the 2nd cycle.
Study NCT02285530 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery group
Description: Radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.
Study NCT02285530 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery group
Description: Radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.
Study NCT02285530 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Post-operative radiotherapy
Description: Radiotherapy was arranged 4 to 6 weeks after surgery. Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed and the dose was 1.8-2 Gy/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
Study NCT02285530 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Post-operative radiotherapy
Description: Radiotherapy was arranged 4 to 6 weeks after surgery. Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed and the dose was 1.8-2 Gy/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
Study NCT01014455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informing surgical patients about CO monitoring
Description: A brief intervention that recommends preoperative fasting from cigarettes and that informs patients that their smoking status will be checked before surgery using inhaled CO monitoring will decrease their exposure to cigarette smoke prior to surgery
Study NCT01014455 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: a brief intervention recommending preoperative abstinence from smoking
Description: a brief intervention that recommends fasting but does not mention that CO will be checked
Study NCT03510325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Commonly used oral antipsychotics intervention therapy.
Study NCT01908257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad 400 mg + ranitidine 150 mg
Study NCT01061242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep promoting interventions
Description: MICU staff will implement multi-faceted, staged sleep promoting interventions as part of a pre-existing sleep quality improvement project.
Study NCT00312091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine, nevirapine, and stavudine fixed-dose tablet
Description: 7 mg d4T, 30 mg 3TC, 50 mg NVP tablet
Study NCT00312091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Dosage dependent on weight. More information on this criterion can be found in the protocol.
Study NCT00312091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: Dosage dependent on weight. More information on this criterion can be found in the protocol.
Study NCT00312091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stavudine
Description: Dosage dependent on weight. More information on this criterion can be found in the protocol.
Study NCT03961607 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aminolevulinic acid photodynamic therapy
Description: Aminolevulinic acid photodynamic therapy
Study NCT03961607 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aminolevulinic acid photodynamic therapy
Description: Aminolevulinic acid photodynamic therapy
Study NCT03090854 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ADASCog
Description: Neuropsychological test
Study NCT01053689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride tablets 1 mg
Study NCT01053689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride tablets 1 mg
Study NCT04497077 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tart cherry
Description: Either tart cherry juice or freeze dried powdered tart cherry in capsule was given
Study NCT01882439 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tofacitinib
Description: tablets, 10 mg BID x 3 months
Study NCT03068182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm crank
Description: Each participant practiced on arm crank (Hudson) from long sitting position for 40 minutes. Seat's height and distance were adjusted to achieve full extension of subject arms at horizontal shoulder-level position
Study NCT03068182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treadmill
Description: Participant practiced on an electronic computerized treadmill for 40 minutes . participant began warming up with lowest speed treadmill exercise for 5 minutes at zero inclination. Treadmill speed was increased gradually to achieve the pre-determined individualized moderate intensity for 30 minutes
Study NCT03068182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT04269629 — intervention group
Intervention type: DRUG
Intervention: Insect Venom
Description: Patients receive insect venom immunotherapy. The frequency of systemic side-effects is recorded and compared between patients under antihypertensive treatment and patients not taking antihypertensive drugs.
Study NCT03710460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg, one per day before breakfast during 12 weeks.
Study NCT03004339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOR007 Ointment 0.15%
Study NCT03004339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SOR007 Ointment Placebo
Study NCT03004339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taclonex® Ointment
Study NCT02488954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotics in the form of cheese portion
Study NCT04497077 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo
Description: either cornstarch capsule or kool-aid
Study NCT04218734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBPR108
Description: DBPR108: 100 mg, once daily for 24 weeks.
Study NCT04218734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: metformin hydrochloride: 500 mg, 1-3 times daily for 24 weeks.
Study NCT04218734 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin hydrochloride
Description: metformin hydrochloride: 500 mg, 1-3 times daily for 24 weeks.
Study NCT03710460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin plus Metformin XR
Description: 10/1000 mg, one per day before breakfast during 12 weeks.
Study NCT03710460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: 1000 mg, one per day before breakfast during 12 weeks.
Study NCT03510325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Commonly used oral antipsychotics intervention therapy.
Study NCT03510325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Commonly used oral antipsychotics intervention therapy.
Study NCT04063059 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PRIDE counseling intervention
Description: Step-by-Step program to create positive lifestyle change geared toward wellness and long term healthy living through group sessions and telephone counseling.
Study NCT00642343 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of motor proficiency skills.
Description: The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
Study NCT00642343 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of motor proficiency
Description: The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
Study NCT01051869 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simple decompression
Description: Fracture fixation will be performed through a posterior approach, as this provides excellent visualization of the distal fragments. A triceps split will be used to expose the distal humerus. A midline incision will be made from proximally to distal onto the shaft of the ulna. Equal portions of the triceps muscle will be reflected medially and laterally, with use of sharp dissection to remove the triceps insertion from the olecranon. The ulnar nerve will be identified and protected proximal and distal to the medial epicondyle. Fracture fixation will be performed after anatomic reduction using standard fixation techniques and plate fixation on both the medial and lateral column.~In the simple ulnar nerve decompression group, no further treatment of the ulnar nerve will be undertaken.
Study NCT01051869 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anterior subcutaneous transposition
Description: In the anterior transposition of the ulnar nerve group, the ulnar nerve will be placed subcutaneously anterior to the medial epicondyle free from any pressure.
Study NCT03200574 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 4D Cardiac CT Scan
Description: 4D CT scan obtained at minimum of 1 month after the discontinuation of the anticoagulation or dual antiplatelet therapy
Study NCT03200574 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LivaNova Bioprothetic Aortic Valve Implant
Description: Study includes patients that have received the commercially approved LivaNova bioprosthetic aortic heart valve Perceval, as standard of care.
Study NCT04266496 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: ICIQ FLUTS (women) or MLUTS (mannen) CIVIQ 2 PSQI
Study NCT00642343 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Evaluation of motor proficiency.
Description: The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
Study NCT04354870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Description: Loading dose: 600 mg, oral, 1 day Maintenance dose: 200 mg, oral, daily, for 90 days
Study NCT04218734 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placepo
Description: placebo:100 mg, once daily for 24 weeks.